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Abstract
Introduction: In this study, we evaluated the activity of the neuroendocrine axes in patients with polymyalgia
rheumatica (PMR) before and after tumor necrosis factor (TNF)-a-blocking etanercept treatment, which previously
has been shown to reduce interleukin 6 (IL-6) and C-reactive protein (CRP) markedly in PMR.
Methods: Plasma samples were collected from 10 glucocorticoid-naïve patients with PMR and 10 matched
controls before and after etanercept treatment (25 mg biweekly for 2 weeks). The primary end points were pre-
and posttreatment levels of adrenocorticotropic hormone (ACTH), cortisol, adrenaline, thyroid-stimulating hormone
(TSH), follicle-stimulating hormone (FSH), prolactin, and insulin-like growth factor 1 (IGF-1).
Results: Before TNF-a-blocking treatment, plasma TNF-a, ACTH, and cortisol levels were higher in patients versus
controls (P < 0.05 and P < 0.001, respectively); during TNF-a blockade in patients, levels of both hormones
decreased (P < 0.05 and P < 0.01, respectively), whereas levels in controls increased (P < 0.05), abolishing the
pretreatment differences. Pretreatment adrenaline levels were more than twice as high in patients than in controls
(P < 0.01); after treatment in patients, levels had decreased (P < 0.05) but remained higher versus controls (P <
0.05). Levels of the other hormones never differed significantly between groups (P > 0.05).
Conclusions: In PMR, TNF-a may increase the activities of the hypothalamic-pituitary-adrenal and the
hypothalamic-sympthoadrenomedullary axes. Secretion of TSH, FSH, prolactin, and IGF-1 is not clearly changed in
PMR.
Trial registration: ClinicalTrials.gov (NCT00524381).
Introduction
Polymyalgia rheumatica (PMR) is the most common
chronic inflammatory rheumatic disease in the elderly [1].
Clinical symptoms include tenderness, aching, and stiffness
in proximal parts of the limbs [1,2]. Based on histologic
and imaging evidence, PMR is commonly seen as reflecting
inflammation in synovial structures (that is, joints, bursae,
and tendon sheaths). Recently, however, we have found
that primary muscle pathology is probably also involved in
the pathophysiology of PMR [3,4]. Correspondingly, PMR
symptoms may be seen in the absence of imaging evidence
of synovial inflammation, and, conversely, such evidence
may be present without PMR symptoms or remain after
such symptoms have disappeared [5,6]. Paraclinically, PMR
is associated with increased erythrocyte sedimentation rate
(ESR), as well as increased blood levels of C-reactive pro-
tein (CRP) and of proinflammatory cytokines [7] (for
example, interleukin (IL) 6 [1,3,8-11] and, in some studies,
tumor necrosis factor (TNF)-a [3,8,11-15]).
Based on TNF-a-blocking studies, it has been concluded
that in rheumatoid arthritis (RA) and other chronic
inflammatory diseases, such as ankylosing spondylitis,
psoriasis, and Crohn disease, increased concentrations of
TNF-a are associated with neuroendocrine changes,
including dysfunctional hypothalamic-pituitary-adrenal
(HPA), hypothalamic-pituitary-gonadal (HPG), hypothala-
mus-pituitary-liver-muscle, and hypothalamic-autonomic
nerve system (HANS) axes (reviewed in [16]).
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In PMR, knowledge of the potential pathophysiologic
involvement of (neuro)endocrine dysfunction in general
and the impact of TNF-a blocking in particular is mod-
est. We previously showed that PMR is associated with
decreased insulin sensitivity [8]. Reports of normal basal
thyroid-stimulating hormone (TSH) [17] and prolactin
concentrations [17,18] in plasma, normal [17] or elevated
[2] 17-hydroxyprogesterone (17-OHP) and reduced dehy-
droepiandrosterone [19] responses to adrenocorticotro-
pic hormone (ACTH) [2], and normal [17,20] or low [19]
basal levels of androstenedione are also available. How-
ever, most focus has been on cortisol secretion. Challen-
ging the immediate expectation (that is, that the HPA
axis would be enhanced, the predominant view has been
that, in contrast, it is impaired in PMR [2,19-21]. This
view is in line with the facts that PMR symptoms are
reminiscent of adrenocortical insufficiency and the ster-
oid-withdrawal syndrome [2,16,22], and that symptoms
are ameliorated by exogenous glucocorticoid administra-
tion. However, basal plasma concentrations of ACTH
and cortisol have been found to be normal, and not
reduced, in PMR [2,11,17,19,20,23]. Still, although not
reduced, ACTH and cortisol secretion can be regarded as
low relative to inflammation status [2,19-21]. This view is
based on studies showing increased levels of ACTH and
cortisol in response to IL-6 injection in humans
[12,14,15].
In a recent randomized controlled trial, we explored
the clinical effect of TNF-a blockade in glucocorticoid-
naïve PMR patients [13]. However, the administration of
a TNF-a blocker can also be used to elucidate the role
of TNF-a in pathophysiologic mechanisms. So, to
extend further the understanding of the role of the auto-
nomic (neuro)endocrine system in the pathophysiology
of PMR and with particular emphasis on the involve-
ment of TNF-a in endocrine activity, we have now, in a
subset of patients and healthy control subjects from that
trial, measured the plasma levels of various hormones
reflecting the activity of all of the anterior pituitary hor-
mone axes as well as of the sympathoadrenal system
before and after 14 days of TNF-a-blocking treatment
with etanercept. To our knowledge, this is the first




Subject characteristics and trial protocols were previously
described in detail [13]. In brief, 20 glucocorticoid-naïve
patients with untreated, newly diagnosed PMR according
to the Chuang criteria [24], as well as 20 healthy control
subjects, were randomized in a 1:1 ratio to treatment for
14 days with the soluble Fc-coupled TNF-a receptor eta-
nercept (Enbrel; Wyeth Pharmaceuticals New Lane,
Hampshire, UK) or placebo (saline). Exclusion criteria
were as follows: prior or current use of glucocorticoids or
other immunosuppressive drugs; signs of giant cell arteri-
tis, including cranial symptoms of vasculitis (headache,
visual disturbances, jaw claudication, abnormal pulsation
of wall of the temporal artery, scalp tenderness); infec-
tions with systemic impact; hepatitis B or C infection;
positive tuberculosis-screening tests (thorax x-ray ima-
ging, Mantoux skin test, and Quantiferon tuberculosis
blood test); positive blood or urine culture; uncontrolled
diabetes mellitus; uncontrolled hypertension; severe heart
failure (New York Heart Association class 3 and 4); other
inflammatory diseases than PMR; cancer in the past
5 years; neuromuscular disease; thyroid disease; or distur-
bance of calcium homeostasis. Control subjects fulfilled
the same exclusion criteria as patients and were matched
according to sex, age, and body mass index (BMI).
All scientific and technical personnel were blinded to
group assignment. In the present investigation, only the
subjects treated with etanercept were included (10
patients with PMR and 10 control subjects).
Concurrent use of glucocorticoids and nonsteroidal
antiinflammatory drugs was not allowed; other usual
medications were allowed, but subjects were not
included if treated with drugs with potential impact on
study end points [13]. Until the day of experiments, for
pain control, the centrally active opioid-like analgesic
tramadol (Mandolgin; Sandoz A/S, Odense, Denmark)
was administered according to needs.
The study was approved by the Danish Medicines
Agency (approval number 2612-3497) and The Ethical
Committee of the Capital Region (approval number H-
D-2007-0040), and it was entered in the EUdract (num-
ber 2007-003009) and clinicaltrials.gov (NCT00524381)
databases. Before inclusion in the study, all participants
signed a written informed consent.
Protocol
Subjects were examined before and after treatment with
etanercept for 14 days (biweekly subcutaneous injections
with 25 mg Enbrel). In the morning before each exami-
nation, subjects were allowed to take their prescribed
medications but abstained from tramadol. On both
examinations, after an overnight fast, subjects arrived at
08:00 hours to the laboratory by taxi. Between 08:00 and
09:00, after at least 15 min of rest in a chair, blood sam-
ples were drawn from a cannulated forearm vein. In
addition, a clinical examination of joint mobility as well
as muscle function and tenderness was performed.
Finally, remaining data for calculation of the PMR activ-
ity score (PMR-AS) were collected (see Study end
points).
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Study end points
In the present study, as the primary end points, we mea-
sured plasma levels of ACTH, cortisol, adrenalin, folli-
cle-stimulating hormone (FSH), prolactin, TSH, and
insulin-like growth factor 1 (IGF-1), and adrenalin
before and after etanercept treatment. In addition,
PMR-AS was calculated from plasma CRP levels, the
duration of morning stiffness, the ability to raise arms,
as well as physician’s global assessment and subject’s
assessment of pain (visual analogue scales) [13].
Blood samples
Blood samples were drawn in stock EDTA Vacutainers
with added aprotinin (Trasylol; proteolysis inhibitor);
plasma was harvested by centrifugation at 1,200 rpm
and 4°C for 15 minutes and frozen at -80°C until analy-
sis within 6 months. In separate Vacutainers, blood was
drawn for immediate ESR and CRP measurements.
Analytic methods
Plasma levels were determined by using enzyme-linked
immunosorbent assay (ELISA) kits; specific kits were
(detection limit): ACTH, ALPCO 21-ACTHU-E01 (0.22
pg/ml); cortisol, Labor Diagnostic Nord GmbH (LDN) MS
E-5000 (0.4 μg/ml); adrenalin, LDN BA E-5100 (3.9 pg/
ml); FSH, LDN FR E-2400 (1 IU/L); prolactin, LDN FR
E-2900 (10 μIU/ml); TSH, LDN TF E-3000 (0.05 μIU/ml);
and IGF-1, Mediagnost E20 (0.09 ng/ml). Details on mea-
surement of blood ESR and CRP as well as of plasma IL-6
and TNF-a were given in reference [13]. All analyses of a
given hormone were carried out in duplicate and in a sin-
gle assay.
Statistics
Statistical analysis was performed by using SPSS 20.0 for
Mac (SPSS Inc., Chicago, IL, USA). Comparisons within
patients (paired data) and comparisons between patients
and controls (unpaired data) were performed by using the
Wilcoxon signed-rank test and the Mann-Whitney U test,
respectively (two-way analysis of variance tests returned
the same significances). P values < 0.05 in two-tailed test-
ing were considered significant. Data in figures are given
as medians and interquartile ranges. To allow comparison
with previous reports, most of these data are also given in
the Results section as mean ± SEM.
Results
Baseline anthropometrics, including age, BMI, and blood
pressure, did not differ between groups; ESR and CRP as
well as IL-6 and TNF-a were significantly higher in
patients with PMR versus control subjects (Table 1) [13].
As previously reported [13], before treatment, PMR dis-
ease activity, as measured by the PMR-AS, was signifi-
cantly higher in patients with PMR than in controls
subjects (P < 0.0001 to 0.001); in patients after etanercept
treatment, PMR-AS had decreased significantly by 24%
(95% confidence interval, 12% to 33%; P = 0.011) but
remained markedly higher than in controls (P < 0.0001
to 0.001). In response to etanercept treatment in patients,
ESR, CRP, and IL-6 decreased but remained significantly
higher than in controls (Table 1). TNF-a levels increased
in both patients and controls because of accumulation of
etanercept-TNF-a complexes [13]. After 14 days of eta-
nercept therapy, patients commenced prednisolone treat-
ment (20 mg/day), which within a week induced
complete clinical remission and normalized ESR and
CRP levels, supporting the PMR diagnosis (data not
shown).
ACTH and cortisol
Before TNF-a-blocking treatment, levels of ACTH and
cortisol (Figure 1) were significantly higher (P = 0.04 and
P < 0.0001, respectively) in patients (26.4 ± 4.5 pg/ml and
52.6 ± 2.6 μg/dl, respectively) than in controls (15.3 ± 2.4
pg/ml and 25.5 ± 2.9 μg/dl, respectively). In patients with
TNF-a blockade, ACTH (20.6 ± 2.6; P = 0.045) and corti-
sol (37.9 ± 2.5; P = 0.005) decreased. In contrast, in con-
trol subjects, levels of both ACTH (18.6 ± 2.7; P = 0.04)
and cortisol (33.6 ± 2.6; P = 0.03) increased with TNF-a
blockade. Consequently, postblockade levels of neither
cortisol nor ACTH differed between patients and con-
trols (P > 0.05).
Ratios between ACTH and cortisol, respectively, and CRP
or IL-6
Before TNF-a-blocking treatment, ACTH/CRP (patients
5.9 ± 1.7 versus controls 15.3 ± 2.4, P = 0.006), cortisol/
CRP (patients 11.8 ± 2.7 versus controls 25.5 ± 2.9; P =
0.002), ACTH/IL-6 (patients 0.7 ± 0.1 versus controls
9.3 ± 2.8; P = 0.007), and cortisol/IL-6 (patients 1.4 ± 0.2
versus controls 16.8 ± 3.9; P = 0.0008) ratios were signifi-
cantly lower in patients than in controls (Figure 2). With
treatment, these ratios significantly increased in patients
(ACTH/CRP 12.9 ± 4.2; P = 0.049; cortisol/CRP 20.9 ±
4.8; P = 0.02; ACTH/IL-6 1.7 ± 0.6; P = 0.046; cortisol/
IL-6 2.7 ± 0.6; P = 0.01) but remained lower (P < 0.05)
than in controls ACTH/CRP 18.6 ± 2.7, cortisol/CRP
33.6 ± 2.6, ACTH/IL-6 22.4 ± 8.6, cortisol/IL-6 20.8 ±
2.9) (Figure 2).
Adrenalin
Before TNF-a-blocking treatment, levels of adrenalin
(Figure 3) were considerably higher in patients com-
pared with controls (patients 0.11 ± 0.02 versus controls
0.051 ± 0.007 ng/ml; P = 0.007); with TNF-a blockade,
levels in patients (0.077 ± 0.006; P = 0.03) but not in
controls (0.046 ± 0.009; P > 0.05) decreased, but levels
in patients remained higher (P = 0.03) than in controls.
Kreiner and Galbo Arthritis Research & Therapy 2012, 14:R186
http://arthritis-research.com/content/14/4/R186
Page 3 of 10
TSH, FSH, prolactin, and IGF-1
Levels of TSH, FSH, and prolactin (Figure 4) as well as
of IGF-1 (Figure 5) did not differ significantly between
groups before or after TNF-a blockade. However, levels
of TSH, FSH, and IGF-1 tended (P < 0.1) to be lower in
patients than in controls both before and after treat-
ment, whereas mean levels of prolactin were always
higher in the patients (P < 0.1).
Discussion
The major new finding of the present study is that in
glucocorticoid-naïve patients with PMR, the plasma con-
centrations of ACTH and cortisol, as well as of adrena-
lin, may be increased compared with findings in healthy
controls. Furthermore, these differences were abolished
and reduced, respectively, during 14 days of TNF-a-
blocking treatment with etanercept. Levels of TSH, FSH,
and IGF-1 tended to be lower, and those of prolactin,
higher, in patients than in controls before as well as
after treatment, but differences did not achieve statistical
significance, and concentrations were not influenced by
etanercept treatment.
ACTH and cortisol
In previous studies, basal concentrations of ACTH and
cortisol in plasma were found to be normal [1,2,11,
17,19,20]. Furthermore, supporting the view that the HPA
axis is intact in PMR, stimulation with corticotropin-
releasing hormone (CRH) produced normal ACTH and
cortisol responses [1,2], whereas stimulation with ACTH
has been found to elicit either normal [2-4], increased
[5,6,19], or slightly, if at all, reduced [7,17] cortisol
responses. Still, it has been proposed that in PMR, the
HPA axis is inhibited and that this may contribute to the
Table 1 Characteristics of patients and control subjects before and after etanercept treatment
Patients (n = 10) Control subjects (n = 10)
Before After Before After
Sex (female/male) 6/4 - 9/1 -
Age (years) 72.6 ± 2.6 - 69.6 ± 1.2 -
Onset-to-study duration (range; months) 8.7 ± 2.2 (2-20) - - -
BMI (kg/m2) 23.6 ± 3.4 - 22.5 ± 0.9 -
Blood pressure (systolic/diastolic, mm Hg) 160 ± 5/87 ± 4 - 148 ± 5/85 ± 3 -
Smokers (n) 2 - 2 -
Hypertension (n) 6 - 5 -
Hypercholesterolemia (n) 3 - 2 -
ESR (mm/h) 71.1 ± 8.4 56.6 ± 12.6a 11.0 ± 3.1e 9.4 ± 2.8e
CRP (mg/dl) 7.5 ± 1.9 3.5 ± 1.2b 1.1 ± 0.1e < 1.0e
IL-6 (pg/ml) 76.4 ± 31.3 22.1 ± 4.4c 4.1 ± 1.6e 4.7 ± 1.8e
TNF-a (pg/ml) 9.1 ± 1.6 16.9 ± 2.6d 3.8 ± 0.5e 16.4 ± 3.2d
Data are expressed as mean ± SEM. aValues are high due to accumulation of TNF-a/etanercept complexes; for details, please see reference [13]. bP = 0.049 versus







































Patients untreated Patients treated Controls untreated Controls treated
Cortisol
Figure 1 Plasma levels of adrenocorticotropic hormone (ACTH) and cortisol before (gray bars) and after (white bars) 14 days of TNF-
a-blocking treatment with etanercept in glucocorticoid-naïve patients with polymyalgia rheumatica (PMR) and in non-PMR control
subjects. Box plots show median values and 25% to 75% interquartile ranges. Symbols connected by full lines represent values for individual
subjects. Dashed lines represent tendencies between medians of paired data. *P < 0.05; **P < 0.01; ***P < 0.001.
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symptoms [2,19]. Although not reduced in absolute terms
in PMR, cortisol secretion may be relatively impaired and
inadequate relative to inflammation [25]. This is so,
because plasma cortisol levels may be lower than expected,
because concentrations of various cytokines (for example,
IL-6) are increased [1,3,8-11], and because in non-PMR
patients, injection with IL-6 has been shown to increase
ACTH and cortisol levels in plasma [3,8,11-15]. Emphasis
has been put on ratios between concentrations of hor-
mones and inflammatory variables (for example, cortisol/
CRP and ACTH/CRP) [17,26]. In line with a previous study
in PMR [17], we also found that before treatment, these
ratios as well as cortisol/IL-6 and ACTH/IL-6 ratios were
significantly lower in patients than in controls (Figure 2).
Nonetheless, an important addition of the present
study to existing evidence is that in untreated PMR,
increased basal levels of ACTH and cortisol in plasma
may also be found (Figure 1), indicating activation of the
HPA axis, as seen in other stress conditions [27].
Whether, in the present study, the activation of the HPA
axis was less than expected (from the concomitant
increased levels of inflammatory cytokines) is difficult to
tell. For instance, before etanercept treatment, cortisol
concentrations were 110% higher in PMR patients com-
pared with controls, and this difference corresponds with
what one would expect from the IL-6 plasma concentra-
tion difference between the two groups and the relation
between cortisol and IL-6 concentrations determined by
IL-6 injections in healthy subjects [15,25]. However, in
PMR, IL-6 is most likely only one of the variables
involved in a complex overall setting of the hypothalamus
stimulation from inflammatory and other factors, and
dose-effect studies intending to mimic the simultaneous
influence of all changes in the internal milieu seen in
inflammatory conditions have not been performed. That
ratios between hormones and cytokines are difficult to
interpret is illustrated by the fact that, even though
serum cortisol and IL-6 concentrations were linearly
related in the quoted study of IL-6 injections [15], calcu-



























































































Patients untreated Patients treated Controls untreated Controls treated
Cortisol/IL-6 ratios
Figure 2 Ratios between plasma levels of ACTH and cortisol, respectively, and IL-6 or CRP before (gray bars) and after (white bars)
14 days of TNF-a-blocking treatment with etanercept in glucocorticoid-naïve patients with polymyalgia rheumatica (PMR) and in non-
PMR control subjects. Box plots show median values and 25% to 75% interquartile ranges. Symbols connected by full lines represent values for
individual subjects. Dashed lines represent tendencies between medians of paired data. *P < 0.05; **P < 0.01; ***P < 0.001.
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increasing IL-6 concentrations, because the regression
line did not originate in the (0,0).
One possible explanation for the differences in ACTH
and cortisol levels between our study and previous studies
is that before treatment with etanercept, disease activity in
our patients was higher than that of previously studied
patients. Thus, mean ESR and CRP levels in our study
before treatment were 71 mm/h and 7.5 mg/dl, respec-
tively, whereas mean values in previous investigations,
which did not find increased ACTH and cortisol levels,
were 34 to 72 mm/h (range) and 0.7-4.9 mg/dl, respec-
tively [2,11,17,21,23]. In the present study, after TNF-a-
blocking treatment with etanercept, ESR and CRP had
declined to values (means, 57 mm/h and 3.5 mg/dl,
respectively) comparable to the mean values in the pre-
vious investigations, and this was accompanied by some,
albeit modest, clinical improvement [13]. So, the normali-
zation of ACTH and cortisol concentrations during TNF-a
blocking with etanercept was associated with a reduction
in disease activity.
Another factor that might explain the differences in
HPA activity between studies could be that in previous
studies, disease onset-to-study duration (published dura-
tions, weeks ± SD: 11.2 ± 8 [11]; 19.2 ± 10.4 [17];
10.4 ± 0.8 [2]; 30.7 ± 24 [20]; and 10.8 ± 10 [23]) was
longer compared with the present study (mean 8.7 ±
12.5 weeks, Table 1), allowing, in the former studies, a
spontaneous reduction in HPA axis activity as seen in
critical illness [28] or adaptation of the hypothalamus
to, for example, increased stimulation with inflammatory
cytokines [25]. An increase and subsequent decrease of
ACTH and cortisol has been proposed to be evolutiona-
rily advantageous, for example, in severe systemic infec-
tion [25]. Our new finding of enhanced HPA-axis
activity adds to existing evidence by indicating that such
a time course exists in PMR.
The mechanism for the depicted decline in HPA activ-
ity is unclear [25]. A downregulation of hypothalamic
activity in response to maintained stimulation by cyto-
kines has been proposed [25]. Compatible with this idea,
ACTH responses were diminished from the beginning to
the end of studies of patients with cancer injected daily
with IL-6 for 7 or 21 days [12,14]. However, cortisol

















Patients untreated Patients treated Controls untreated Controls treated
Adrenaline
Figure 3 Plasma levels of adrenalin before (gray bars) and after (white bars) 14 days of TNF-a[blocking treatment with etanercept in
glucocorticoid-naïve patients with polymyalgia rheumatica (PMR) and in non-PMR control subjects. Box plots show median values and
25% to 75% interquartile ranges. Symbols connected by full lines represent values for individual subjects. Dashed lines represent tendencies
between medians of paired data. *P < 0.05; **P < 0.01.
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the diminished ACTH responses to IL-6 by feedback
inhibition from cortisol rather than reflecting hypothala-
mic adaptation to IL-6 [12,14].
The second major finding of the present study is that
TNF-a is probably involved in the stimulation of the
HPA axis in PMR. This is so because we found that the
stimulation was abolished during 14 days of TNF-a-
blocking etanercept treatment (Figure 1). Supporting
that, in the patients, the effect of etanercept did in fact
reflect TNF-a blockade and was not unspecific, in the
control subjects, the effect of the agent on ACTH and
cortisol was opposite that seen in the patients (Figure 1).
At variance with the present findings, based on a study of
RA patients treated with anti-TNF-a antibody, it was pro-
posed that prolonged elevation of serum TNF-a inhibits
ACTH secretion at the hypothalamic or pituitary level
[29]. However, in contrast to this suggestion, mean ACTH
and cortisol levels apparently decreased during the initial 2
weeks of treatment and were, on average, not altered dur-
ing 16 weeks of observation [29]. Correspondingly, in
another study, plasma cortisol concentrations increased
during 12 weeks of TNF-a blockade in RA patients with
initially relatively low cortisol levels, but cortisol levels
decreased in patients with relatively high levels [30]. Over-
all, mean concentrations apparently did not change. It was
speculated that the findings reflected the existence of two
types of RA patients with remarkably different TNF-a
influence on the HPA axis [30]. It may also be speculated
that statistical regression toward the mean played a role
for the observed differential response.
Adrenalin
As would be expected in acute inflammation, in PMR
patients in the present study, activation of the HPA axis
was paralleled by an increased activity in the sympa-
thetic nervous system, as indicated by increased adrena-
line concentrations in plasma (Figure 3). Furthermore,
in response to the TNF-a blockade, adrenaline secretion
was ameliorated along with HPA axis activity (Figures 1


















































Patients untreated Patients treated Controls untreated Controls treated
TSH
Figure 4 Plasma levels of follicle-stimulating hormone (FSH), prolactin, and thyroid-stimulating hormone (TSH) before (gray bars) and
after (white bars) 14 days of TNF-a-blocking treatment with etanercept in glucocorticoid-naïve patients with polymyalgia rheumatica
(PMR) and in non-PMR control subjects. Box plots show median values and 25% to 75% interquartile ranges. Symbols connected by full lines
represent values for individual subjects. Dashed lines represent tendencies between medians of paired data. *P < 0.05.
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previously been concluded that sympathetic nervous sys-
tem activity is increased in RA [31]. In systemic lupus
erythematosus, sympathetic outflow has been found to
be increased as judged from neuropeptide Y (NPY) con-
centrations in serum [32]. In contrast, no increase in
NPY concentration was found in patients with RA, who
were not treated with glucocorticoids [32]. The effect of
anti-TNF-a treatment was studied in the latter patients;
NPY concentrations were not influenced by the treat-
ment, a finding which is not surprising considering the
fact that concentrations were not increased before treat-
ment [32]. Chromogranin A (CHGA) is a less specific
marker of neuroendocrine secretion, the plasma concen-
tration of which may be increased in RA [33]. No
change in CHGA levels was found in RA patients trea-
ted for 6-14 weeks with anti-TNF-a antibody [33].
Prolactin, TSH, FSH, and IGF-1
The findings in the present study of borderline signifi-
cant increase in plasma prolactin and decreases in TSH,
FSH, and IGF-1 (Figures 4 and 5) are compatible with a
time course of hormonal changes in PMR similar to
that described for critical illness [28]. In the early phase
of critical illness, anterior pituitary secretion increases,
whereas in prolonged disease, secretion is gradually sup-
pressed [28]. The normal co-variation between GH
secretion and IGF-1 levels in plasma is partially dis-
rupted, IGF-1 levels being low throughout critical illness
[28].
In previous studies of PMR patients, prolactin and TSH
concentrations did not differ significantly from concen-
trations in control subjects [17,26]; however, in accor-
dance with our findings, concentrations tended to be
increased and decreased, respectively [17,26]. In a num-
ber of other inflammatory diseases, including RA, ele-
vated levels of prolactin have been found [34]. The HPG
axis, here monitored with FSH, and the hypothalamus-
pituitary-liver-muscle axis, here monitored by IFG-1,
have not previously been studied in PMR, nor has the
effect of TNF-a blockade on neuroendocrine activity. We
found no effect of TNF-a blockade on plasma prolactin,



















Patients untreated Patients treated Controls untreated Controls treated
IGF-1
Figure 5 Plasma levels of insulin-like growth factor 1 (IGF-1) before (gray bars) and after (white bars) 14 days of TNF-a-blocking
treatment with etanercept in glucocorticoid-naïve patients with polymyalgia rheumatica (PMR) and in non-PMR control subjects. Box
plots show median values and 25% to 75% interquartile ranges. Symbols connected by full lines represent values for individual subjects. Dashed
lines represent tendencies between medians of paired data.
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and 5). This is in contrast to the findings in healthy sub-
jects, that IL-6 injection may increase concentrations of
prolactin and GH, whereas both IL-6 injection and TNF-
a infusion may reduce plasma TSH [15,35]. In contrast
to the latter observation, in RA patients, anti-TNF-a
treatment for 28 weeks has been found to decrease TSH
levels in plasma [36]. However, the decrease in TSH
levels was larger in hypothyroid than in euthyroid
patients, a difference that probably reflected that the
effect of the TNF-a-blocking treatment on TSH secre-
tion in part was secondary to improved thyroid gland
function [36].
Conclusions
The present study has shown that in PMR, TNF-a-
dependent mechanisms may enhance the activity of the
HPA axis and of the sympathoadrenal system. The evi-
dence for changes in secretion of other pituitary hor-
mones and IGF-1 is ambiguous, and this secretion is
not influenced by TNF-a blockade.
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